FundedHere Header Logo
NephTech Pte Ltd
NephTech Pte Ltd is a medical technology company dedicated to helping dialysis centres elevate the standard of care for patients. Through a user-centric approach to remote surveillance and management of Vascular Access (VA) for End Stage Renal Disease (ESRD) patients, the programme improves the predictability of stenosis and therefore the outcomes for patients, as well as driving productivity in the dialysis centre through optimization of workflow.
$X,000,000
Y% undefined $X,000,000
Z
7 years ago
Overview

Quick Pitch

NephTech prides itself as a provider of a user-centric, non-invasive blood vessel surveillance for dialysis centres and kidney failure patients to improve on the current deficit for early detection of stenotic events.

Product/Service Details

An integrated system of sensory hardware, proprietary predictive signal algorithm and cloud computing technologies, NephTech’s first-of-its-kind non-invasive measurement solution seeks to allow patients, care-givers and dialysis centres to identify early stage renal disease complications within seconds.

Problem/Opportunity

End Stage Renal Disease (“ESRD”) is the final stage of chronic kidney disease, culminating in a loss of kidney functions. A typical treatment plan will involve an organ transplant (an 8-year waiting list in Singapore) or ongoing dialysis treatment programme – 3 treatment sessions per week (4 hours per treatment session) for the rest of their lives. 

Treating ESRD with dialysis treatment is complex and financially draining. Vascular surgeons have to create a ‘special’ blood vessel in patients, allow the blood vessel to mature over a 3-month period before dialysis nurses can use this matured blood vessel for dialysis treatments. Through the frequent needling of this blood vessel during dialysis treatments, the blood vessel becomes prone to complications, including blood vessel narrowing (stenosis) leading up to formation of blood clot (thrombosis). Current commonly used technique to monitor requires at least 15 minutes of preparation, calibration and measurement, making it very inefficient. There are clinical evidence demonstrating cost saving benefits with early detection of these complications.

Solution

NephTech, a Singapore-based medical technology company, has been quietly revolutionising this process.

Using an integrated system of sensory hardware, proprietary predictive signal algorithm and cloud computing technologies, NephTech’s first-of-its-kind non-invasive, needle-less measurement solution seeks to allow patients, care-givers and dialysis centres to identify early stage renal disease complications within seconds. The principle behind this predictive technology has also been demonstrated scientifically to be accurate. 

Traction & Accomplishments

The company has undergone independent assessments of NephTech business viability, market potential and technical capability, made by experienced panellists from the MedTech industry.

  • Recipient of NTU MDT Ignition Grant SGD 10,000
  • TECS | SPRING grant SGD 250,000
  • Collaboration works with NTU, SGH, NKF Singapore, KDF & NKF Malaysia
  • Winner of Inaugural Microsoft Startup Challenge (Access to Microsoft technical support)
  • Enrolled into Income FutureStarter, NTUC Income - SG Innovate Accelerator Program  (Access to Reimbursement Strategy, Philips Healthcare platform)
    • In talks of potential implementation of a 12-month pilot test on Income insured
  • Featured on ChannelNewsAsia as demonstration of one of Singapore’s promising innovations into deep technology

How We're Different

Commercial Opportunities:

  • High intangible assets from regional patient data collection and intellectual property ownership
  • Respective revenue generation models for product range – including a subscription model, licensing and joint ventures
  • Ahead of plans for market outreach strategies in target Asia Pacific countries, with early collaborative clinical partners for clinical test bedding
  • Ready parties from China, Thailand, Indonesia and Australia interested to roll out early technology assessments
  • Subsequent potential for joint ventures and commercialization into peripheral markets by industry partners

Revenue model:

  • Market Segmentation of personal application and commercial application
  • Validated pricing strategy by industry experts - sale of external hardware sensor (handheld device) SGD 5,000 per device; annual surveillance service SGD 15,000 per dialysis centre
  • Additional revenue stream: consumable replacement & service contract
  • On-track development of personal application for hemodialysis patients

Team

Co-founders: Dr. James Lim & Ms. Toh Yanling

Ms. Edwina Alias (Acoustic Signal Processing), Mr Wang Shengxiao (Quality Management System) & Mr. Srimanta Mohanty (Backend Architecture)

Advisors/ Investors/ Stakeholders:

  • Distinguished investors and mentors, ranging from the clinical, technical and private equity industries, such as Jeremy Lim from Oliver Wyman and Andy Lim from Tembusu Partners
  • Established relationships with prominent vascular surgeons and nephrologists whom are currently working with the Nephtech team to develop the product with the intention of being eventual paying customers
  • Supported by International Key Opinion Leaders 

Contact

[email protected] / [email protected]

$Y,000,000
SGDNaN
equity
D